Select Publications
Journal articles
2018, 'Utility of Using the Montreal Cognitive Assessment (MoCA) as a Screening Tool for HIV-Associated Neurocognitive Disorders (HAND) In Multi-Ethnic Malaysia', AIDS and Behavior, 22, pp. 3226 - 3233, http://dx.doi.org/10.1007/s10461-018-2073-x
,2018, 'No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts', AIDS, 32, pp. 985 - 997, http://dx.doi.org/10.1097/QAD.0000000000001778
,2018, 'The high frequency of autoantibodies in HIV patients declines on antiretroviral therapy', Pathology, 50, pp. 313 - 316, http://dx.doi.org/10.1016/j.pathol.2017.10.017
,2018, 'Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy', AIDS, 32, pp. 35 - 48, http://dx.doi.org/10.1097/QAD.0000000000001685
,2018, 'Covertly active and progressing neurochemical abnormalities in suppressed HIV infection', Neurology: Neuroimmunology and NeuroInflammation, 5, pp. &na, http://dx.doi.org/10.1212/NXI.0000000000000430
,2017, 'HIV-related cognitive decline despite viral suppression and complex confounds in American women', Neurology, 89, pp. 1540 - 1541, http://dx.doi.org/10.1212/WNL.0000000000004503
,2017, 'HIV-Associated neurocognitive disorders: A global perspective', Journal of the International Neuropsychological Society, 23, pp. 860 - 869, http://dx.doi.org/10.1017/S1355617717001102
,2017, 'Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedure', Journal of Clinical and Experimental Neuropsychology, 39, pp. 753 - 767, http://dx.doi.org/10.1080/13803395.2016.1263282
,2017, 'Does HIV prematurely age the brain?', The Lancet HIV, 4, pp. e380 - e381, http://dx.doi.org/10.1016/S2352-3018(17)30108-X
,2017, 'Erratum to: White matter measures are near normal in controlled HIV infection except in those with cognitive impairment and longer HIV duration (Journal of NeuroVirology, (2017), 23, 4, (539-547), 10.1007/s13365-017-0524-1)', Journal of NeuroVirology, 23, pp. 548 - 549, http://dx.doi.org/10.1007/s13365-017-0542-z
,2017, 'White matter measures are near normal in controlled HIV infection except in those with cognitive impairment and longer HIV duration', Journal of NeuroVirology, 23, pp. 539 - 547, http://dx.doi.org/10.1007/s13365-017-0524-1
,2017, 'Monitoring HIV-Associated Neurocognitive Disorder Using Screenings: a Critical Review Including Guidelines for Clinical and Research Use', Current HIV/AIDS Reports, 14, pp. 83 - 92, http://dx.doi.org/10.1007/s11904-017-0349-9
,2017, 'Cognitive change trajectories in virally suppressed HIV-infected individuals indicate high prevalence of disease activity', PLOS ONE, 12, http://dx.doi.org/10.1371/journal.pone.0171887
,2017, 'Socioeconomic factors explain suboptimal adherence to antiretroviral therapy among HIV-infected Australian adults with viral suppression', PLoS ONE, 12, pp. e0174613, http://dx.doi.org/10.1371/journal.pone.0174613
,2017, 'Cognitive Change Trajectories in Virally Suppressed HIV-Infected Individuals Indicate High Prevalence of Disease Activity', PLoS One, 12, pp. e0171887, http://dx.doi.org/10.1371/journal.pone.0171887
,2016, 'Reduced cellular energy as a potential marker of HIV brain latency related neuropathogenesis: a pilot study', JOURNAL OF NEUROVIROLOGY, 22, pp. S76 - S77, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000394093700158&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2016, 'A Screening Strategy for HIV-Associated Neurocognitive Disorders That Accurately Identifies Patients Requiring Neurological Review', Clinical Infectious Diseases, 63, pp. 687 - 693, http://dx.doi.org/10.1093/cid/ciw399
,2016, 'Short communication: Do cytomegalovirus antibody levels associate with age-related syndromes in HIV patients stable on antiretroviral therapy?', AIDS Research and Human Retroviruses, 32, pp. 567 - 572, http://dx.doi.org/10.1089/aid.2015.0328
,2016, 'Identifying neurocognitive decline at 36 months among HIV-positive participants in the CHARTER cohort using group-based trajectory analysis', PLoS ONE, 11, pp. e0155766, http://dx.doi.org/10.1371/journal.pone.0155766
,2016, 'Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder', AIDS, 30, pp. 591 - 600, http://dx.doi.org/10.1097/QAD.0000000000000951
,2016, 'The role of depression chronicity and recurrence on neurocognitive dysfunctions in HIV-infected adults', Journal of NeuroVirology, 22, pp. 56 - 65, http://dx.doi.org/10.1007/s13365-015-0368-5
,2016, 'Understanding and optimizing brain health in HIV now: protocol for a longitudinal cohort study with multiple randomized controlled trials', BMC NEUROLOGY, 16, http://dx.doi.org/10.1186/s12883-016-0527-1
,2016, 'The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review', CNS Drugs, 30, pp. 53 - 69, http://dx.doi.org/10.1007/s40263-015-0302-7
,2015, 'Advancing research in NeuroAIDS using collaboration and public data sharing', BMC Medical Genomics, 8, http://dx.doi.org/10.1186/s12920-015-0150-9
,2015, 'Initiation of antiretroviral therapy in early asymptomatic HIV infection', New England Journal of Medicine, 373, pp. 795 - 807, http://dx.doi.org/10.1056/NEJMoa1506816
,2015, 'The role of depression chronicity and recurrence on neurocognitive dysfunctions in HIV-infected adults', Journal of NeuroVirology, http://dx.doi.org/10.1007/s13365-015-0368-5
,2015, 'HIV eradication symposium: will the brain be left behind?', Journal of NeuroVirology, 21, pp. 322 - 334, http://dx.doi.org/10.1007/s13365-015-0322-6
,2015, 'Peripheral blood mononuclear cells HIV DNA levels impact intermittently on neurocognition', PLoS ONE, 10, pp. e0120488, http://dx.doi.org/10.1371/journal.pone.0120488
,2015, 'APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - A cross-sectional observational study', BMC Neurology, 15, pp. 51, http://dx.doi.org/10.1186/s12883-015-0298-0
,2015, 'Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial', HIV MEDICINE, 16, pp. 97 - 108, http://dx.doi.org/10.1111/hiv.12238
,2015, 'Editorial commentary: Should longitudinal multisite studies become the new standard for investigating neurocognitive functions in HIV infection?', Clinical Infectious Diseases, 60, pp. 481 - 482, http://dx.doi.org/10.1093/cid/ciu863
,2015, 'HIV infection and obstructive sleep apnea: Why epidemiological data are needed', Journal of Applied Physiology, 118, pp. 248 - 249, http://dx.doi.org/10.1152/japplphysiol.00989.2014
,2015, 'Lessons to be learned from the largest study of cognition in American women with HIV disease', Neurology, 84, pp. 220 - 221, http://dx.doi.org/10.1212/WNL.0000000000001166
,2015, 'O4‐10‐02: Cross‐cultural differences in instrumental activities of daily living (IADL): Translations and adaptations of the amsterdam iadl questionnaire', Alzheimer's & Dementia, 11, http://dx.doi.org/10.1016/j.jalz.2015.07.400
,2014, 'Primary HIV infection alters brain neurochemistry, but does antiretroviral treatment help?', Neurology, 83, pp. 1588 - 1589, http://dx.doi.org/10.1212/WNL.0000000000000947
,2014, 'Symptoms of depression and rates of neurocognitive impairment in HIV positive patients in Beijing, China', Journal of Affective Disorders, 162, pp. 89 - 95, http://dx.doi.org/10.1016/j.jad.2014.03.038
,2014, 'HIV-associated neurocognitive disorder in Australia: a case of a high-functioning and optimally treated cohort and implications for international neuroHIV research', Journal of NeuroVirology, 20, pp. 258 - 268, http://link.springer.com/article/10.1007/s13365-014-0242-x
,2014, 'Is the HIV dementia scale a reliable tool for assessing HIV-relatedneurocognitive decline?', Journal of AIDS and Clinical Research, 5, http://dx.doi.org/10.4172/2155-6113.1000269
,2014, 'The effects of HIV and aging on brain functions: Proposing a research framework and update on last 3 years' findings', Current Opinion in HIV and AIDS, 9, pp. 355 - 364, http://dx.doi.org/10.1097/COH.0000000000000078
,2014, 'HIV-associated neurocognitive disorder in Australia: a case of a high-functioning and optimally treated cohort and implications for international neuroHIV research', Journal of NeuroVirology, 20, pp. 258 - 268, http://dx.doi.org/10.1007/s13365-014-0242-x
,2013, 'HIV Chemoprophylaxis for Adolescents: Educable Moment, Not Magic Bullet', CLINICAL INFECTIOUS DISEASES, 56, pp. 1156 - 1158, http://dx.doi.org/10.1093/cid/cis1026
,2013, 'The cost of silencing HIV in the brain', Neurology, 80, pp. 1363 - 1364, http://dx.doi.org/10.1212/WNL.0b013e31828c3077
,2013, 'Assessment, diagnosisand treatment of Human Immunodeficiency Virus (HIV)-associated neurocognitive disorders (HAND): A consensus report of the mind exchange program', Clinical Infectious Diseases, 56, pp. 1004 - 1017, http://dx.doi.org/10.1093/cid/cis975
,2013, 'HIV, Vascular and Aging Injuries in the Brain of Clinically Stable HIV-Infected Adults: A 1H MRS Study', PLoS One, 8, pp. Article numbere61738, http://dx.doi.org/10.1371/journal.pone.0061738
,2013, 'Validity of Cognitive Screens for HIV-Associated Neurocognitive Disorder: A Systematic Review and an Informed Screen Selection Guide', Current HIV/AIDS Reports, 10, pp. 342 - 355, http://dx.doi.org/10.1007/s11904-013-0176-6
,2012, 'Characteristics of neurocognitive decline in virally-suppressed middle-aged HIV plus individuals', JOURNAL OF NEUROVIROLOGY, 18, pp. 26 - 26, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000304487800054&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2012, 'Relationships between genetic markers of neuroinflammation, neurodegeneration and neurocognitive impairment in controlled HIV infection', JOURNAL OF NEUROVIROLOGY, 18, pp. 23 - 24, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000304487800048&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2012, 'CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion', Neurology, 78, pp. 690 - 695, http://dx.doi.org/10.1212/WNL.0b013e318249f683
,2012, 'Comments to Garvey et al.: "low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy"', HIV Clinical Trials, 13, pp. 296 - 298, http://dx.doi.org/10.1310/hct1305-296
,2012, 'Cerebrovascular disease in HIV-infected individuals in the era of highly active antiretroviral therapy', Journal of Neurovirology, 18, pp. 264 - 276, http://dx.doi.org/10.1007/s13365-012-0092-3
,